Antitumor activity of MLN4924, a novel small molecule inhibitor of Nedd8-activating enzyme, in pre-clinical models of lymphoma

被引：0
|
作者：
Smith, Peter G. [1 ]
Milhollen, Michael [1 ]
Traore, Tary [1 ]
Zhang, Julie [1 ]
Berger, Allison [1 ]
Yu, Jie [1 ]
Garnsey, James [1 ]
Langston, Steve [1 ]
Soucy, Teresa [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3602S / 3602S
页数：1
相关论文
共 50 条
  • [1] Azacitidine/Decitabine Synergism with the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML Models
    Smith, Peter G.
    Traore, Tary
    Grossman, Steve
    Narayanan, Usha
    Carew, Jennifer S.
    Lublinksky, Anya
    Kuranda, Michael
    Milhollen, Michael
    BLOOD, 2011, 118 (21) : 267 - 267
  • [2] Pre-Clinical Antitumor activity of MLN4924, An Inhibitor of NEDD8-Activating Enzyme (NAE), in a Novel Primary Human DLBCL Xenograft Model
    Traore, Tary
    Garnsey, James J.
    Koenig, Erik
    Berger, Allison J.
    Manfredi, Mark G.
    Petruzzelli, Lilli
    Smith, Peter G.
    BLOOD, 2009, 114 (22) : 382 - 382
  • [3] Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma.
    Traore, T.
    Mihollen, M.
    Garnsey, J.
    Berger, A.
    Manfredi, M.
    Cosmopolous, K.
    Donelan, J.
    Smith, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Clinical pharmacodynamic assay development for the first small molecule inhibitor of Nedd8-activating enzyme (NAE), MLN4924
    Garnsey, James Joseph
    Walker, Russell M.
    Pickard, Michael D.
    Traore, Tary
    Thomas, Michael
    Zhang, Julie
    Xia, Cindy
    Zhang, Ji
    Mulligan, George
    Smith, Peter G.
    Berger, Allison J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [5] SYNERGISTIC COMBINATION OF MLN4924, AN INVESTIGATIONAL SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), WITH AZACITIDINE, A HYPOMETHYLATING AGENT, IN PRE-CLINICAL AML CANCER MODELS
    Traore, T.
    Milhollen, M.
    Grossman, S.
    Thomas, M.
    Narayanan, U.
    Garnsey, J.
    HAEMATOLOGICA, 2012, 97 : 435 - 435
  • [6] Treatment Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML and DLBCL Models
    Milhollen, Michael
    Thomas, Michael
    Traore, Tary
    Narayanan, Usha
    Riceberg, Jessica
    Sells, Todd
    Amidon, Ben
    Manfredi, Mark
    Bence, Neil
    Brownell, James
    Dick, Larry
    Koenig, Erik
    Gavin, James
    Smith, Peter G.
    BLOOD, 2011, 118 (21) : 615 - 615
  • [7] Preclinical evaluation of MLN4924, the first small molecule inhibitor of NEDD8-activating enzyme (INAE) for the treatment of cancer
    Soucy, Teresa
    Smith, Peter
    Milhollen, Michael
    Berger, Allison
    Davis, Barbara
    Yang, Hua
    Lublinsky, Anya
    Zhang, Julie
    Traore, Tary
    Narayanan, Usha
    Yu, Jie
    Garnsey, James
    Gavin, James
    Weatherhead, Gabriel
    Cullis, Courtney
    Olhava, Edward
    Vyskocil, Stepan
    Rolfe, Mark
    Langston, Steven
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3521S
  • [8] Mechanistic RBC Partitioning Studies of MLN4924, a Nedd8-Activating Enzyme inhibitor
    Xia, Cindy Q.
    Chen, Susan
    Zhang, Ji
    Wu, Jing-Tao
    Qian, Mark G.
    Lee, Frank W.
    Balani, Suresh K.
    DRUG METABOLISM REVIEWS, 2010, 42 : 94 - 95
  • [9] A Gatekeeper Residue for NEDD8-Activating Enzyme Inhibition by MLN4924
    Toth, Julia I.
    Yang, Li
    Dahl, Russell
    Petroski, Matthew D.
    CELL REPORTS, 2012, 1 (04): : 309 - 316
  • [10] MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
    Nawrocki, Steffan T.
    Griffin, Patrick
    Kelly, Kevin R.
    Carew, Jennifer S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1563 - 1573
12345